Therapy Areas: Oncology
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation
3 August 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has entered into a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-...
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
3 August 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, announced on Monday that the US Food and D...
CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring
3 August 2026 - CTC intelligence company CelLBxHealth plc (AIM: CLBX) on Monday announced a peer-reviewed study demonstrating the use of its Parsortix platform to detect antibody-drug conjugate (ADC)-...
Qatar approves Zepzelca combination as first-line maintenance therapy for extensive-stage small cell lung cancer
3 August 2026 - Swedish pharmaceutical company Immedica, backed by investment firms KKR & Co Inc (NYSE:KKR) and Impilo, announced on Monday that Qatar's Ministry of Public Health has approved...
Coiled Therapeutics doses first patient with optimised AO-252 formulation
3 August 2026 - Coiled Therapeutics plc (AIM: COIL) (OTCQB: COTXF), a clinical-stage precision oncology company, announced on Monday that it has dosed the first patient in the US with an optimised lip...
GlycoNex commences dosing in Phase I trial of GNX1021 in Japan
3 August 2026 - GlycoNex Inc (TPEx:4168), a Taiwan-based, clinical-stage biopharmaceutical company, announced on Sunday that the first participant has been successfully dosed in the First-in-Human (FI...